Drugs Market Research Reports & Industry Analysis

The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.

Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.

A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.

Publications found: 9,295

Sort by:

Bone Disorders (Musculoskeletal Disorders) - Drugs in Development, 2021

US$ 2,000.00

Bone Disorders (Musculoskeletal Disorders) - Drugs in Development, 2021 SUMMARY Bone Disorders (Musculoskeletal Disorders) - Drugs in Development, 2021 provides an overview of the Bone Disorders pipel...

April 2021 95 pages

Bone Fracture (Musculoskeletal) - Drugs in Development, 2021

US$ 2,000.00

Bone Fracture (Musculoskeletal) - Drugs in Development, 2021 SUMMARY Bone Fracture (Musculoskeletal) - Drugs in Development, 2021 provides an overview of the Bone Fracture pipeline landscape. The repo...

April 2021 55 pages

Bone Regeneration (Musculoskeletal) - Drugs in Development, 2021

US$ 2,000.00

Bone Regeneration (Musculoskeletal) - Drugs in Development, 2021 SUMMARY Bone Regeneration (Musculoskeletal) - Drugs in Development, 2021 provides an overview of the Bone Regeneration pipeline landsca...

April 2021 45 pages

Bone Sarcoma (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Bone Sarcoma (Oncology) - Drugs in Development, 2021 SUMMARY Bone Sarcoma (Oncology) - Drugs in Development, 2021 provides an overview of the Bone Sarcoma pipeline landscape. The report provides compr...

April 2021 35 pages

Born Small For Gestational Age (SGA) (Women's Health) - Drugs in Development, 2021

US$ 2,000.00

Born Small For Gestational Age (SGA) (Women's Health) - Drugs in Development, 2021 SUMMARY Born Small For Gestational Age (SGA) (Women's Health) - Drugs in Development, 2021 provides an overview of th...

April 2021 30 pages

Brachyury Protein (Protein T or T) - Drugs in Development, 2021

US$ 3,000.00

Brachyury Protein (Protein T or T) - Drugs in Development, 2021 SUMMARY Brachyury Protein (Protein T or T) - Drugs in Development, 2021 provides in depth analysis on Brachyury Protein (Protein T or T)...

April 2021 30 pages

Brain Cancer (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Brain Cancer (Oncology) - Drugs in Development, 2021 SUMMARY Brain Cancer (Oncology) - Drugs in Development, 2021 provides an overview of the Brain Cancer pipeline landscape. The report provides compr...

April 2021 90 pages

Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Drugs in Development, 2021

US$ 3,000.00

Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Drugs in Development, 2021 SUMMARY Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Drugs in Development, 2021 provides in depth analys...

April 2021 40 pages

Brain (Head) Trauma (Other Diseases) - Drugs in Development, 2021

US$ 2,000.00

Brain (Head) Trauma (Other Diseases) - Drugs in Development, 2021 SUMMARY Brain (Head) Trauma (Other Diseases) - Drugs in Development, 2021 provides an overview of the Brain (Head) Trauma pipeline lan...

April 2021 30 pages

Brain Hemorrhage (Central Nervous System) - Drugs in Development, 2021

US$ 2,000.00

Brain Hemorrhage (Central Nervous System) - Drugs in Development, 2021 SUMMARY Brain Hemorrhage (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Brain Hemorrhage pipel...

April 2021 30 pages

Brain Tumor (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Brain Tumor (Oncology) - Drugs in Development, 2021 SUMMARY Brain Tumor (Oncology) - Drugs in Development, 2021 provides an overview of the Brain Tumor pipeline landscape. The report provides comprehe...

April 2021 75 pages

Brenner Tumor (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Brenner Tumor (Oncology) - Drugs in Development, 2021 SUMMARY Brenner Tumor (Oncology) - Drugs in Development, 2021 provides an overview of the Brenner Tumor pipeline landscape. The report provides co...

April 2021 30 pages

Bronchiolitis Obliterans (Respiratory) - Drugs in Development, 2021

US$ 2,000.00

Bronchiolitis Obliterans (Respiratory) - Drugs in Development, 2021 SUMMARY Bronchiolitis Obliterans (Respiratory) - Drugs in Development, 2021 provides an overview of the Bronchiolitis Obliterans pip...

April 2021 35 pages

Burkholderia Infections (Infectious Disease) - Drugs in Development, 2021

US$ 2,000.00

Burkholderia Infections (Infectious Disease) - Drugs in Development, 2021 SUMMARY Burkholderia Infections (Infectious Disease) - Drugs in Development, 2021 provides an overview of the Burkholderia Inf...

April 2021 35 pages

Burkitt Lymphoma (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Burkitt Lymphoma (Oncology) - Drugs in Development, 2021 SUMMARY Burkitt Lymphoma (Oncology) - Drugs in Development, 2021 provides an overview of the Burkitt Lymphoma pipeline landscape. The report pr...

April 2021 110 pages

C-C Chemokine Receptor Type 2 (Monocyte Chemoattractant Protein 1 Receptor or CD192 or CCR2) - Drugs in Development, 2021

US$ 3,000.00

C-C Chemokine Receptor Type 2 (Monocyte Chemoattractant Protein 1 Receptor or CD192 or CCR2) - Drugs in Development, 2021 SUMMARY C-C Chemokine Receptor Type 2 (Monocyte Chemoattractant Protein 1 Rece...

April 2021 35 pages

C-C Chemokine Receptor Type 9 (G Protein Coupled Receptor 28 or GPR 9-6 or CDw199 or CCR9) - Drugs in Development, 2021

US$ 3,000.00

C-C Chemokine Receptor Type 9 (G Protein Coupled Receptor 28 or GPR 9-6 or CDw199 or CCR9) - Drugs in Development, 2021 SUMMARY C-C Chemokine Receptor Type 9 (G Protein Coupled Receptor 28 or GPR 9-6...

April 2021 30 pages

Cachexia (Musculoskeletal) - Drugs in Development, 2021

US$ 2,000.00

Cachexia (Musculoskeletal) - Drugs in Development, 2021 SUMMARY Cachexia (Musculoskeletal) - Drugs in Development, 2021 provides an overview of the Cachexia pipeline landscape. The report provides com...

April 2021 50 pages

Calcineurin (Protein Serine/Threonine Phosphatase 3 or Protein Phosphatase 3 or EC 3.1.3.16) - Drugs in Development, 2021

US$ 3,000.00

Calcineurin (Protein Serine/Threonine Phosphatase 3 or Protein Phosphatase 3 or EC 3.1.3.16) - Drugs in Development, 2021 SUMMARY Calcineurin (Protein Serine/Threonine Phosphatase 3 or Protein Phospha...

April 2021 80 pages

Calcium Activated Neutral Protease (Calpain or CANP or CAPN or EC 3.4.22.) - Drugs in Development, 2021

US$ 3,000.00

Calcium Activated Neutral Protease (Calpain or CANP or CAPN or EC 3.4.22.) - Drugs in Development, 2021 SUMMARY Calcium Activated Neutral Protease (Calpain or CANP or CAPN or EC 3.4.22.) - Drugs in De...

April 2021 30 pages

Calcium Activated Potassium Channel - Drugs in Development, 2021

US$ 3,000.00

Calcium Activated Potassium Channel - Drugs in Development, 2021 SUMMARY Calcium Activated Potassium Channel - Drugs in Development, 2021 provides in depth analysis on Calcium Activated Potassium Chan...

April 2021 35 pages

Calcium Release Activated Calcium Channel Protein 1 (Protein Orai 1 or Transmembrane Protein 142A or ORAI1) - Drugs in Development, 2021

US$ 3,000.00

Calcium Release Activated Calcium Channel Protein 1 (Protein Orai 1 or Transmembrane Protein 142A or ORAI1) - Drugs in Development, 2021 SUMMARY Calcium Release Activated Calcium Channel Protein 1 (Pr...

April 2021 40 pages

Calcium Sensing Receptor - Drugs in Development, 2021

US$ 3,000.00

Calcium Sensing Receptor - Drugs in Development, 2021 SUMMARY Calcium Sensing Receptor - Drugs in Development, 2021 provides in depth analysis on Calcium Sensing Receptor targeted pipeline therapeutic...

April 2021 35 pages

Calcium/Calmodulin Dependent Protein Kinase Type II (CAMK2 or EC 2.7.11.17) - Drugs in Development, 2021

US$ 3,000.00

Calcium/Calmodulin Dependent Protein Kinase Type II (CAMK2 or EC 2.7.11.17) - Drugs in Development, 2021 SUMMARY Calcium/Calmodulin Dependent Protein Kinase Type II (CAMK2 or EC 2.7.11.17) - Drugs in...

April 2021 35 pages

Calreticulin (Calregulin or Endoplasmic Reticulum Resident Protein 60 or CRP55 or HACBP or grp60 or CALR) - Drugs in Development, 2021

US$ 3,000.00

Calreticulin (Calregulin or Endoplasmic Reticulum Resident Protein 60 or CRP55 or HACBP or grp60 or CALR) - Drugs in Development, 2021 SUMMARY Calreticulin (Calregulin or Endoplasmic Reticulum Residen...

April 2021 35 pages

cAMP Specific 3',5' Cyclic Phosphodiesterase 4B (DPDE4 or PDE32 or PDE4B or EC 3.1.4.53) - Drugs in Development, 2021

US$ 3,000.00

cAMP Specific 3',5' Cyclic Phosphodiesterase 4B (DPDE4 or PDE32 or PDE4B or EC 3.1.4.53) - Drugs in Development, 2021 SUMMARY cAMP Specific 3',5' Cyclic Phosphodiesterase 4B (DPDE4 or PDE32 or PDE4B o...

April 2021 30 pages

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Drugs in Development, 2021

US$ 3,000.00

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Drugs in Development, 2021 SUMMARY Cancer/Testi...

April 2021 50 pages

Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1) - Drugs in Development, 2021

US$ 3,500.00

Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1) - Drugs in Development, 2021 SUMMARY Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1) - Drugs in Development, 2021 provides in depth analysis on Cannabinoid...

April 2021 375 pages

Cannabinoid Receptor 2 (CB2 or CX5 or CNR2) - Drugs in Development, 2021

US$ 3,500.00

Cannabinoid Receptor 2 (CB2 or CX5 or CNR2) - Drugs in Development, 2021 SUMMARY Cannabinoid Receptor 2 (CB2 or CX5 or CNR2) - Drugs in Development, 2021 provides in depth analysis on Cannabinoid Rece...

April 2021 375 pages

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Drugs in Development, 2021

US$ 3,000.00

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) - Drugs in Development, 2021 SUMMARY Carb...

April 2021 40 pages

Carbonic Anhydrase (Carbonate Dehydratase or Carbonic Acid Anhydrase or Carboxyanhydrase or CA or EC 4.2.1.1) - Drugs in Development, 2021

US$ 3,000.00

Carbonic Anhydrase (Carbonate Dehydratase or Carbonic Acid Anhydrase or Carboxyanhydrase or CA or EC 4.2.1.1) - Drugs in Development, 2021 SUMMARY Carbonic Anhydrase (Carbonate Dehydratase or Carbonic...

April 2021 30 pages

Carcinoembryonic Antigen (CEA) - Drugs in Development, 2021

US$ 3,000.00

Carcinoembryonic Antigen (CEA) - Drugs in Development, 2021 SUMMARY Carcinoembryonic Antigen (CEA) - Drugs in Development, 2021 provides in depth analysis on Carcinoembryonic Antigen (CEA) targeted pi...

April 2021 30 pages

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Drugs in Development, 2021

US$ 3,000.00

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Drugs in Development, 2021 SUMMARY Carcinoembryonic Antigen Re...

April 2021 35 pages

Carcinoid Tumor (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Carcinoid Tumor (Oncology) - Drugs in Development, 2021 SUMMARY Carcinoid Tumor (Oncology) - Drugs in Development, 2021 provides an overview of the Carcinoid Tumor pipeline landscape. The report provi...

April 2021 30 pages

Carcinomas (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Carcinomas (Oncology) - Drugs in Development, 2021 SUMMARY Carcinomas (Oncology) - Drugs in Development, 2021 provides an overview of the Carcinomas pipeline landscape. The report provides comprehensi...

April 2021 45 pages

Cardiometabolic Disease (Metabolic Disorders) - Drugs in Development, 2021

US$ 2,000.00

Cardiometabolic Disease (Metabolic Disorders) - Drugs in Development, 2021 SUMMARY Cardiometabolic Disease (Metabolic Disorders) - Drugs in Development, 2021 provides an overview of the Cardiometaboli...

April 2021 40 pages

Cardiomyopathy (Cardiovascular) - Drugs in Development, 2021

US$ 2,000.00

Cardiomyopathy (Cardiovascular) - Drugs in Development, 2021 SUMMARY Cardiomyopathy (Cardiovascular) - Drugs in Development, 2021 provides an overview of the Cardiomyopathy pipeline landscape. The rep...

April 2021 55 pages

Cardiovascular Inflammation (Cardiovascular) - Drugs in Development, 2021

US$ 2,000.00

Cardiovascular Inflammation (Cardiovascular) - Drugs in Development, 2021 SUMMARY Cardiovascular Inflammation (Cardiovascular) - Drugs in Development, 2021 provides an overview of the Cardiovascular I...

April 2021 30 pages

Cardiovascular Risk Factors (Cardiovascular) - Drugs in Development, 2021

US$ 2,000.00

Cardiovascular Risk Factors (Cardiovascular) - Drugs in Development, 2021 SUMMARY Cardiovascular Risk Factors (Cardiovascular) - Drugs in Development, 2021 provides an overview of the Cardiovascular R...

April 2021 35 pages

Carotid Artery Stenosis (Cardiovascular) - Drugs in Development, 2021

US$ 2,000.00

Carotid Artery Stenosis (Cardiovascular) - Drugs in Development, 2021 SUMMARY Carotid Artery Stenosis (Cardiovascular) - Drugs in Development, 2021 provides an overview of the Carotid Artery Stenosis...

April 2021 30 pages

Cartilage Degeneration (Musculoskeletal) - Drugs in Development, 2021

US$ 2,000.00

Cartilage Degeneration (Musculoskeletal) - Drugs in Development, 2021 SUMMARY Cartilage Degeneration (Musculoskeletal) - Drugs in Development, 2021 provides an overview of the Cartilage Degeneration p...

April 2021 40 pages

Casein Kinase 2 (CSNK2 or EC 2.7.11.1) - Drugs in Development, 2021

US$ 3,000.00

Casein Kinase 2 (CSNK2 or EC 2.7.11.1) - Drugs in Development, 2021 SUMMARY Casein Kinase 2 (CSNK2 or EC 2.7.11.1) - Drugs in Development, 2021 provides in depth analysis on Casein Kinase 2 (CSNK2 or...

April 2021 35 pages

Casein Kinase I Isoform Alpha (CKI Alpha or CK1 or CSNK1A1 or EC 2.7.11.1) - Drugs in Development, 2021

US$ 3,000.00

Casein Kinase I Isoform Alpha (CKI Alpha or CK1 or CSNK1A1 or EC 2.7.11.1) - Drugs in Development, 2021 SUMMARY Casein Kinase I Isoform Alpha (CKI Alpha or CK1 or CSNK1A1 or EC 2.7.11.1) - Drugs in De...

April 2021 35 pages

Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) - Drugs in Development, 2021

US$ 3,000.00

Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) - Drugs in Development, 2021 SUMMARY Casein Kinase I Isoform Delta (Tau Protein Kinase C...

April 2021 30 pages

Caspase 1 (Interleukin 1 Beta Convertase or Interleukin 1 Beta Converting Enzyme or p45 or CASP1 or EC 3.4.22.36) - Drugs in Development, 2021

US$ 3,000.00

Caspase 1 (Interleukin 1 Beta Convertase or Interleukin 1 Beta Converting Enzyme or p45 or CASP1 or EC 3.4.22.36) - Drugs in Development, 2021 SUMMARY Caspase 1 (Interleukin 1 Beta Convertase or Inter...

April 2021 35 pages

Caspase (CASP or EC 3.4.22.) - Drugs in Development, 2021

US$ 3,000.00

Caspase (CASP or EC 3.4.22.) - Drugs in Development, 2021 SUMMARY Caspase (CASP or EC 3.4.22.) - Drugs in Development, 2021 provides in depth analysis on Caspase (CASP or EC 3.4.22.) targeted pipeline...

April 2021 30 pages

CD276 Antigen (B7 Homolog 3 or 4Ig B7 H3 or Costimulatory Molecule or CD276) - Drugs in Development, 2021

US$ 3,000.00

CD276 Antigen (B7 Homolog 3 or 4Ig B7 H3 or Costimulatory Molecule or CD276) - Drugs in Development, 2021 SUMMARY CD276 Antigen (B7 Homolog 3 or 4Ig B7 H3 or Costimulatory Molecule or CD276) - Drugs i...

April 2021 30 pages

CD44 Antigen (CDw44 or Epican or Extracellular Matrix Receptor III or GP90 Lymphocyte Homing/Adhesion Receptor or HUTCH I or Heparan Sulfate Proteoglycan or Hermes Antigen or Hyaluronate Receptor or Phagocytic Glycoprotein 1 or CD44) - Drugs in Development, 2021

US$ 3,000.00

CD44 Antigen (CDw44 or Epican or Extracellular Matrix Receptor III or GP90 Lymphocyte Homing/Adhesion Receptor or HUTCH I or Heparan Sulfate Proteoglycan or Hermes Antigen or Hyaluronate Receptor or P...

April 2021 35 pages

Cell Division Control Protein 42 Homolog (G25K GTP Binding Protein or Small GTP Binding Protein CDC42 or CDC42) - Drugs in Development, 2021

US$ 3,000.00

Cell Division Control Protein 42 Homolog (G25K GTP Binding Protein or Small GTP Binding Protein CDC42 or CDC42) - Drugs in Development, 2021 SUMMARY Cell Division Control Protein 42 Homolog (G25K GTP...

April 2021 30 pages

Cells Expressing ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1 (Cyclic ADP Ribose Hydrolase 1 or T10 or 2' Phospho ADP Ribosyl Cyclase/2' Phospho Cyclic ADP Ribose Transferase or ADP Ribosyl Cyclase 1 or CD38 or EC 3.2.2.6 or EC 2.4.99.20) - Drugs in Development, 2021

US$ 3,000.00

Cells Expressing ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1 (Cyclic ADP Ribose Hydrolase 1 or T10 or 2' Phospho ADP Ribosyl Cyclase/2' Phospho Cyclic ADP Ribose Transferase or ADP Ribosyl Cycla...

April 2021 90 pages

Filters

Clear all